IVD Consumable Material Change Forces Process Qualification Before Tooling Changes

A discontinued additive in a resin used for a high-volume in vitro diagnostic consumable forced Flex to qualify a replacement material without disturbing the customer's existing molds or equipment. The decision was not a resin-swap exercise. It was a process-qualification problem with a one-year clock and production lines at risk of shutdown.

Flex (Flex Ltd., a global manufacturing services provider) has supported the diagnostics customer for more than 30 years across product manufacturing, new-product introduction, pilot lines and multiple production locations. When the material supplier announced that the critical additive would be discontinued, the replacement altered molding behavior enough to unsettle the process window. Mold temperature, melt temperature, injection pressure, back pressure, injection speed and cooling time could no longer be treated as interchangeable settings.

That is the point medical plastics buyers should keep: the incumbent material was not replaced because a datasheet looked close. The replacement had to run through the same tools, meet product specifications and preserve production continuity. A qualified material change belongs to the part and process, not just to the compound name.

The IVD part and the one-year limit

The customer needed the transition implemented within one year. Conventional tooling changes were projected at about $300,000 per production line and could have delayed implementation by as much as 18 months. That option failed the schedule before it solved the molding problem.

Flex instead isolated the material change from other variables. Engineers examined multiple production lines, material lots, manufacturing tools and molding conditions. They developed viscosity curves for the replacement material and used a structured testing method to identify which process variables affected part performance most strongly.

The work was conducted as a statistically designed process study rather than a sequence of informal machine adjustments. More than 30 process iterations and more than 13,000 molded components were evaluated before the final parameter set was validated on a production line and deployed to identical lines operating globally.

The principal evidence is not that the new resin could be molded once. It is that the team tested interactions among process variables, selected a process window and then checked that window on production equipment. That is the level of evidence a medical-device change requires when the material sits inside a documented manufacturing system.

The comparable figures below belong to the same IVD material transition and define the economic and timing constraint around the qualification.

The tooling burden was not theoretical in the final decision. Avoiding mold changes across 18 production lines produced reported tooling-cost avoidance of $5.4 million, while the replacement material reduced ongoing material cost by 20%. Those savings matter, but they follow the qualification work; they do not substitute for it.

What the process study proved

The study showed that the replacement material could meet product specifications without changing existing equipment or molds. It also preserved manufacturing continuity and reduced the downstream documentation burden associated with new tooling. Flex reported that the validated transition prevented production-line shutdowns and helped maintain supply reliability.

That result gives processors a useful boundary. A material change can be absorbed by process control when the manufacturer has enough data to distinguish material effects from tool, lot and machine effects. Without that separation, a successful first shot says very little about the production window.

The work also assigns responsibility clearly. The resin supplier controls the formulation change, but the processor and device manufacturer must establish whether the altered formulation changes part quality, process capability, documentation or regulatory continuity. The buyer cannot approve a replacement solely because the incumbent grade is no longer available.

The qualification file, not the press trial

For an IVD consumable, the relevant record needs to connect material lots, tools, lines, process variables and measured parts. Flex's study included those objects. It also used a Design of Experiments approach to examine variable interactions rather than adjusting one machine setting at a time and assuming the result would transfer.

That distinction is where many material-change programs become exposed. A sample run may establish that the replacement fills the cavity. It does not establish that the same material remains within specification across lots, lines and operating conditions. The Flex program went further by validating the selected parameters on a production line and extending them to identical global lines.

The approach also avoided a common false choice between accepting the new material and rebuilding the tool. The replacement resin changed the process, but the process could be redesigned around the material. That only worked because the qualification effort measured the consequences on the actual molded component.

The company's reported 20% material-cost reduction is therefore secondary evidence. The deciding result was the retained process and tooling configuration. A lower resin cost without a validated window would leave the medical-device manufacturer carrying the larger risk: line interruption, documentation changes, supply disruption or a part that passes a short trial but fails under production variation.

The constraint that decides the choice

The incumbent material disappeared from the supply chain because its additive was discontinued. That made substitution unavoidable. The constraint that decided the choice was not a general preference for lower-cost resin or newer materials; it was the need to change material within one year without accepting an 18-month tooling delay or putting production lines at risk.

Flex's result supports a narrow conclusion. In medical injection molding, a material change can be qualified without tooling changes when the manufacturer can identify the process variables that govern part performance, test their interactions at scale and validate the resulting window on production equipment. It does not support a broader claim that any replacement grade can be approved by retuning a press.

QA should refuse the change when the file contains only a supplier equivalence statement or a single successful trial. The defensible approval is the one tied to the molded object, the production line, the material lots and the measured specification. In this case, the material won because the process evidence carried the change—not because the replacement looked interchangeable on paper.